Reverse transcription polymerase chain reaction

Eurofins Technologies Launches an Enhanced Variant of Concern-Discriminating PCR Test Including the South African Variant (B.1.351)

Retrieved on: 
Monday, March 22, 2021
Biotechnology, Pharmaceutical, Managed care, Health, Medical devices, Infectious diseases, Hospitals, Other Health, Molecular biology, Laboratory techniques, Natural sciences, Branches of biology, Biology, Biotechnology, Polymerase chain reaction, Reverse transcription polymerase chain reaction, Eurofins Scientific, Real-time polymerase chain reaction

Eurofins Technologies announces the launch of its GSD NovaType II, its upgraded RT-PCR kit for the identification of mutations associated with SARS-CoV-2 variants of concern.

Key Points: 
  • Eurofins Technologies announces the launch of its GSD NovaType II, its upgraded RT-PCR kit for the identification of mutations associated with SARS-CoV-2 variants of concern.
  • The GSD NovaType II kit delivers results under two hours.
  • It is therefore well suited to timely screening and relieving sequencing capacities for use in epidemiological studies.
  • The assay has been validated on the AriaMxTM and AriaDxTM qPCR platforms from Agilent Technologies and will soon be validated on additional thermocyclers.

Segra International Announces Development and Validation of In-House Assay for Hop Latent Viroid (HLVd)

Retrieved on: 
Thursday, March 18, 2021
Laboratory techniques, Natural sciences, Chemistry, Physical sciences, Molecular biology, Polymerase chain reaction, Biotechnology, Amplifiers, Assay, Reverse transcription polymerase chain reaction, Real-time polymerase chain reaction

This pathogen assay adds to a substantial list of viral, fungal, and bacterial pathogens Segra already test for in-house as part of their Verified Clean Stock program.

Key Points: 
  • This pathogen assay adds to a substantial list of viral, fungal, and bacterial pathogens Segra already test for in-house as part of their Verified Clean Stock program.
  • Rather than relying on older published HLVd detection assays, Segra's real-time RT-PCR assay is based on consensus of current HLVd sequences recorded in Genbank.
  • "Hop Latent Viroid is an increasingly recognized pathogen now showing obvious economic damage in commercial cannabis cultivation globally.
  • Segra has developed industrial-scale laboratories to produce Verified Clean Stock, robust, and DNA-fingerprinted cannabis plantlets for licensed producers globally.

DGAP-News: XPhyto Therapeutics Corp.: XPhyto announces European Approval for 25 Minute COVID-19 PCR Test

Retrieved on: 
Thursday, March 18, 2021
Molecular biology, Laboratory techniques, Natural sciences, Branches of biology, Life sciences, Biotechnology, Polymerase chain reaction, Amplifiers, Reverse transcription polymerase chain reaction, Coronavirus disease, COVID-19 testing, Draft:IGeneX

VANCOUVER, BC / ACCESSWIRE / March 18, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) ("XPhyto" or the "Company"), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"), are pleased to announce the European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system ("Covid-ID Lab").

Key Points: 
  • VANCOUVER, BC / ACCESSWIRE / March 18, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) ("XPhyto" or the "Company"), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"), are pleased to announce the European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system ("Covid-ID Lab").
  • Covid-ID Lab is now registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test.
  • With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic," said Hugh Rogers, CEO and Director of XPhyto.
  • For assay performance, Covid-ID Lab requires only a single 20-minute PCR thermal cycle without prior RNA extraction as part of the sample preparation.

Twist Bioscience Begins Shipping of Synthetic RNA Controls for B.1.351 and P.1 Variants

Retrieved on: 
Monday, March 15, 2021
Infectious diseases, Biotechnology, Genetics, Health, Branches of biology, Biology, Life sciences, Biotechnology, Molecular biology, Laboratory techniques, Polymerase chain reaction, Reverse transcription polymerase chain reaction, Severe acute respiratory syndrome coronavirus, Lineage B.1.1.7, DNA sequencing, Variants of SARS-CoV-2

In addition, Twist began shipping synthetic RNA controls that cover the B.1.1.7 strain of SARS-CoV-2 in a stabilized format that can be shipped and stored at room temperature.

Key Points: 
  • In addition, Twist began shipping synthetic RNA controls that cover the B.1.1.7 strain of SARS-CoV-2 in a stabilized format that can be shipped and stored at room temperature.
  • In March 2020, Twist launched its first synthetic SARS-CoV-2 RNA distinct reference sequences as positive controls for the development of both next-generation sequencing (NGS) and reverse transcription-polymerase chain reaction (RT-PCR) assays to test for SARS-CoV-2.
  • The Twist synthetic controls are designed based on specific SARS-CoV-2 variants, cover the full viral genome and are sequence-verified.
  • Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

BATM launches no-swab saliva-based COVID-19 test

Retrieved on: 
Thursday, March 11, 2021
Laboratory techniques, Molecular biology, Natural sciences, Branches of biology, Biology, Biotechnology, Polymerase chain reaction, COVID-19 testing, Reverse transcription polymerase chain reaction

This significantly improves the sample collection process compared with existing swabbing methods while, as an RT-PCR test, maintaining diagnostic accuracy.

Key Points: 
  • This significantly improves the sample collection process compared with existing swabbing methods while, as an RT-PCR test, maintaining diagnostic accuracy.
  • All standard PCR instruments can execute this test at a rate of c. 150-180 per hour, which (including the extraction phase) is approximately five times the rate for a nasopharyngeal test.
  • "We are extremely proud to have launched this new saliva-based COVID-19 test for samples that are self-collected without the need for swabbing.
  • We have already received particular interest from cruise lines and professional sports teams who see this test as enabling a safe return to more normal life.

Eurofins Launches empowerDX COVID-19 Home Collection Kit on Amazon

Retrieved on: 
Wednesday, March 10, 2021
FDA, Medical devices, Infectious diseases, Health, Pharmaceutical, Articles, COVID-19 testing, Branches of biology, Life sciences, Coronavirus disease, Eurofins Scientific, Reverse transcription polymerase chain reaction, Severe acute respiratory syndrome coronavirus, Draft:FELUDA, Draft:IGeneX

empowerDX , a Eurofins (Paris:ERF) subsidiary, announced the launch of its direct-to-consumer, FDA-emergency use authorised, COVID-19 Home Collection Kit on Amazon.

Key Points: 
  • empowerDX , a Eurofins (Paris:ERF) subsidiary, announced the launch of its direct-to-consumer, FDA-emergency use authorised, COVID-19 Home Collection Kit on Amazon.
  • The empowerDX at-home COVID-19 test can detect the virus in both symptomatic and asymptomatic patients.
  • Eurofins Viracor , an infectious disease testing laboratory for more than 35 years, developed the empowerDX test based on its own FDA EUA authorised SARS-CoV-2 RT-PCR assay.
  • The empowerDX kit is available as a single purchase and as a pack of 10.

PerkinElmer Launches Comprehensive Solutions for Detecting SARS-CoV-2 Mutations

Retrieved on: 
Tuesday, March 9, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Medical devices, Infectious diseases, Coronaviridae, Sarbecovirus, Natural sciences, Laboratory techniques, Variants of SARS-CoV-2, Molecular biology, Biotechnology, 501.V2 variant, Lineage B.1.1.7, Reverse transcription polymerase chain reaction, Severe acute respiratory syndrome coronavirus 2, Polymerase chain reaction

Using nucleic acid extracted from samples that previously tested positive, laboratories can use these assays to identify genomic mutations reported in relation to SARS-CoV-2 variants.

Key Points: 
  • Using nucleic acid extracted from samples that previously tested positive, laboratories can use these assays to identify genomic mutations reported in relation to SARS-CoV-2 variants.
  • Public health agencies such as the U.S. Food and Drug Administration (FDA) have alerted clinical laboratories and the healthcare community about SARS-CoV-2 viral mutations.
  • Upon detecting a positive case using a first-tier diagnostic assay, second-tier assays such as the PerkinElmer PKamp VariantDetect and NEXTFLEX Variant-Seq kits provide further information about mutations in the sample.
  • The PKamp VariantDetect SARS-CoV-2 RT-PCR assay can detect mutations associated with B.1.1.7, B.1.351 and P.1 variants, which are the predominant variant strains known today.

Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection

Retrieved on: 
Tuesday, March 9, 2021
Health, Infectious diseases, Genetics, Other Science, Science, Biotechnology, Molecular biology, Laboratory techniques, Branches of biology, Natural sciences, Articles, Polymerase chain reaction, Biotechnology, Sarbecovirus, Reverse transcription polymerase chain reaction, Real-time polymerase chain reaction, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

Agilent Technologies Inc. (NYSE: A) today announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA.
  • The CE-IVD mark is in accordance with the European Union In Vitro Diagnostic Directive 98/79/EC and is available for immediate distribution.
  • The Agilent SARS-CoV-2 qRT-PCR Dx kit is a real-time reverse transcriptase PCR (qRT-PCR) IVD reagent kit for the detection of SARS-CoV-2 RNA.
  • Agilents kit is intended for the qualitative detection of CDC-recommended1 N1 and N2 targets from SARS-CoV-2 RNA isolated and purified from nasopharyngeal swab specimens.

Meridian Launches its New Air-Dryable Mix for Crude Blood Samples

Retrieved on: 
Monday, March 8, 2021
Natural sciences, Laboratory techniques, Chemistry, Physical sciences, Molecular biology, Biotechnology, Polymerase chain reaction, DNA, Real-time polymerase chain reaction, Assay, Serum, Reverse transcription polymerase chain reaction

Blood sample screening provides a faster and more accurate way for early cancer detection compared to single-site tissue sampling.

Key Points: 
  • Blood sample screening provides a faster and more accurate way for early cancer detection compared to single-site tissue sampling.
  • However, PCR inhibitors in blood specimens can lead to false-negative results or reduced sensitivity unless costly and time-consuming DNA purification methods are used.
  • Meridians Air-Dryable Direct DNA qPCR Blood Mix uses a specialized polymerase and advanced buffer formulation optimized specifically for whole blood, serum and plasma, without the need for purification of DNA from the sample.
  • Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays.

COVID-19 Detection Kits Market Size To Reach $4.63 Billion By 2027, To Be Driven By Constant Growth in Delivery of Molecular Test Kits | Million Insights

Retrieved on: 
Monday, March 8, 2021
Life sciences, Articles, Natural sciences, Biotechnology, Molecular biology, Polymerase chain reaction, Reverse transcription polymerase chain reaction, Coronavirus disease

What are the Driving Factors for the COVID-19 Detection Kits Market?

Key Points: 
  • What are the Driving Factors for the COVID-19 Detection Kits Market?
  • Consequently, the kits for RT-PCR centered molecular analyze are observing a massive augmentation in demand, through the world.
  • The constant growth in the delivery of the molecular test kits describes the towering demand for the COVID-19 detection kits
    Please click here to get the sample pdf and find more details on "COVID-19 Detection Kits Market"Report 2027.
  • Browse 150 page research report with TOC on "Global COVID-19 Detection Kits Market" at: https://www.millioninsights.com/industry-reports/global-covid-19-detecti...
    Million Insights segmented the global COVID-19 detection kits market based on End Use, Mode, Sample Type, Product, and Region:
    COVID-19 Detection Kits Products Outlook (Revenue, USD Million, 2020 - 2027)
    COVID-19 Detection Kits Sample Type Outlook (Revenue, USD Million, 2020 - 2027)